XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
(Thomson Reuters ONE) -
Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary
Thrombosis
AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT)
announced today that research involving MABp1, the company's IL-1 alpha (IL-
1[alpha]) antibody, will be featured in an oral presentation during the American
Heart Association Scientific Sessions being held November 11-15 in Anaheim,
California. The presentation will provide evidence that IL-1[alpha] is
associated with Neutrophil Extracellular Traps (NETs) and is involved in
endothelial activation and thrombogenesis.
Neutrophil Extracellular Traps Increase Endothelial Activation and
Thrombogenicity via IL-1[alpha] and NF-[kappa]B: Implications for
Title: Superficial Erosion
Session: Endothelial Dysfunction in Vascular Disease
Date: Monday, November 13, 2017
Time: 5:45 p.m. - 5:55 p.m. (Pacific Time)
Location: Anaheim Convention Center, Anaheim, CA
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from
individuals who possess natural immunity to certain diseases. With discovery and
clinical programs across multiple disease areas, XBiotech's True Human
antibodies have the potential to harness the body's natural immunity to fight
disease with increased safety, efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly, cost-
effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the date of this
press release. We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise, after the
date of this press release.
Contact
Ashley Otero
aotero(at)xbiotech.com
512-386-2930
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2017 - 17:16 Uhr
Sprache: Deutsch
News-ID 566600
Anzahl Zeichen: 4687
contact information:
Town:
Austin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 289 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions"
steht unter der journalistisch-redaktionellen Verantwortung von
XBiotech, Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
